埃索美拉唑适合什么人用？

Who is suitable for esomeprazole? Esomeprazole is the S-isomer of omeprazole and is suitable for the treatment of gastroesophageal reflux disease (GERD) and erosive reflux esophagitis, long-term maintenance treatment for cured esophagitis patients to prevent recurrence, symptom control of gastroesophageal reflux disease (GERD) combined with appropriate antimicrobial therapy to eradicate Helicobacter pylori, heal duodenal ulcers related to Helicobacter pylori infection, and prevent the recurrence of peptic ulcers related to Helicobacter pylori.

Clinical studies have shown that patients with reflux esophagitis taking esomeprazole 40 mg for 4 weeks have a healing rate of approximately 78% and 93% after 8 weeks. After one week of treatment with esomeprazole 20 mg twice a day in combination with appropriate antibiotics, the eradication rate of Helicobacter pylori is approximately 90%. After one week of eradication therapy, patients with uncomplicated duodenal ulcers no longer need to use acid suppressants alone for follow-up treatment to heal the ulcer and eliminate symptoms.

Effects of Esomeprazole (Nexium) on the Pharmacokinetics of Other Drugs For drugs whose absorption is affected by gastric acid, the absorption of these drugs may be increased or decreased during esomeprazole treatment due to a decrease in gastric acidity. Esomeprazole has no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine. Effect of Other Drugs on Esomeprazole Pharmacokinetics Esomeprazole is metabolized by CYP2C19 and CYP3A4. Coadministration of esomeprazole with the CYP3A4 inhibitor clarithromycin (500 mg twice daily) can double the area under the plasma concentration-time curve (AUC) of esomeprazole. Esomeprazole is contraindicated in persons with known hypersensitivity to esomeprazole, other benzimidazole compounds, or any other component of this product. Esomeprazole, like other proton pump inhibitors, should not be coadministered with atazanavir.